Core Points - Orion Corporation has been awarded the Internationalisation Award of the President of the Republic of Finland in the growth companies category, recognizing its international success and contributions to Finnish expertise and employment [1][2][8] - The company plays a significant role in the global pharmaceutical industry, focusing on drug research, production, and the availability of affordable generic medicines [3][4] - Orion's research and development capabilities are expanding globally, with new facilities opened in Cambridge, UK, and New York City, USA, to foster innovation [4][5] Company Achievements - The award highlights Orion's commitment to high-quality and affordable medicines, particularly in oncology and central nervous system disorders, developed in collaboration with leading research organizations [6][7] - A notable achievement is the prostate cancer drug developed by Orion, which has reached blockbuster status with annual sales of €1 billion, benefiting approximately 175,000 patients [7] Industry Impact - Orion's medicines are utilized in over 100 countries, demonstrating its extensive global influence and the positive impact of its innovations on millions of lives [4][5] - The company emphasizes responsible business practices and aims to attract foreign investment while promoting Finland's innovation environment [2][6]

About this content We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a f ...